Back to Search
Start Over
Understanding blood development and leukemia using sequencing-based technologies and human cell systems.
- Source :
-
Frontiers in molecular biosciences [Front Mol Biosci] 2023 Oct 10; Vol. 10, pp. 1266697. Date of Electronic Publication: 2023 Oct 10 (Print Publication: 2023). - Publication Year :
- 2023
-
Abstract
- Our current understanding of human hematopoiesis has undergone significant transformation throughout the years, challenging conventional views. The evolution of high-throughput technologies has enabled the accumulation of diverse data types, offering new avenues for investigating key regulatory processes in blood cell production and disease. In this review, we will explore the opportunities presented by these advancements for unraveling the molecular mechanisms underlying normal and abnormal hematopoiesis. Specifically, we will focus on the importance of enhancer-associated regulatory networks and highlight the crucial role of enhancer-derived transcription regulation. Additionally, we will discuss the unprecedented power of single-cell methods and the progression in using in vitro human blood differentiation system, in particular induced pluripotent stem cell models, in dissecting hematopoietic processes. Furthermore, we will explore the potential of ever more nuanced patient profiling to allow precision medicine approaches. Ultimately, we advocate for a multiparameter, regulatory network-based approach for providing a more holistic understanding of normal hematopoiesis and blood disorders.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Heuts and Martens.)
Details
- Language :
- English
- ISSN :
- 2296-889X
- Volume :
- 10
- Database :
- MEDLINE
- Journal :
- Frontiers in molecular biosciences
- Publication Type :
- Academic Journal
- Accession number :
- 37886034
- Full Text :
- https://doi.org/10.3389/fmolb.2023.1266697